The effect of etanercept on a case of amyloidosis secondary to ankylosing spondylitis: Results of 2-year follow-up
Acta Reumatologica Portuguesa, cilt.38, sa.4, ss.299-301, 2013 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 38 Sayı: 4
- Basım Tarihi: 2013
- Dergi Adı: Acta Reumatologica Portuguesa
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.299-301
- Anahtar Kelimeler: Ankylosing Spondylitis, secondary amyloidosis, etanercept, renal function
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Secondary amyloidosis (type AA) is rarely encountered but can be a significant complication of ankylosing spondylitis (AS) and may lead to proteinuria and renal dysfunction. Anti-tumor necrosis factor-alpha (anti-TNF-α) agents may be used to induce clinical remission by suppressing systemic inflammation in secondary amyloidosis. The patient described, with the diagnosis of AS, was diagnosed with secondary amyloidosis, despite treatment with disease modifying anti-rheuma -tic medication. He developed marked proteinuria, renal dysfunction and low levels of serum albumin. Diagno sis of amyloidosis was confirmed by renal biopsy. During a 2-year treatment period with etanercept, an anti-TNF-α agent, a definite improvement was determined in all parameters. This case illustrates that in the treatment of secondary amyloidosis related to AS, etanercept, an anti-TNF-α agent, can be consi dered an effective therapeutic option.